证券代码：000705 证券简称：浙江震元 编号：2021-001 | --- | --- | --- | |-----------------------|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系 \n活动类别 | □新闻发布会 | √特定对象调研 □分析师会议 \n□媒体采访 □业绩说明会 \n□路演活动 \n□现场参观 □其他（请文字说明其他活动内容） | | 参与单位 | 融通基金研究员 | | | 名称 | | | | 时间 2021 | 年 9 月 8 | 日星期三下午 | | 地点 公司会议室 | | | | 上市公司 接待人员 | 公司董秘 | | | | 1 、介绍公司情况 | 公 ...

证券代码：000705 证券简称：浙江震元 浙江震元股份有限公司投资者关系活动记录表 | --- | --- | |-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：000705 证券简称：浙江震元 浙江震元股份有限公司投资者关系活动记录表 编号：2021-004 | --- | --- | --- | |-----------------------|--------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系 | | √特定对象调研 □分析师会议 | | 活动类别 | | □媒体采访 □业绩说明会 | | | □新闻发布会 | □路演活动 | | | | □现场参观 □其他（请文字说明其他活动内容） | | 参与单位 名称 | | 兴证证券资产管理有限公司行 ...

证券代码：000705 证券简称：浙江震元 浙江震元股份有限公司投资者关系活动记录表 编号：2021-003 | --- | --- | --- | --- | --- | --- | --- | |-----------------------|--------------------------------|---------------------------------------------------------------------------------------------------|-------|-------|----------------|-------| | 投资者关系 \n活动类别 | | √特定对象调研 □分析师会议 \n□媒体采访 □业绩说明会 | | | | | | | □新闻发布会 | □路演活动 | | | | | | | | □现场参观 □其他（请文字说明其他活动内容） | | | | | | 参与单位 名称 | 万联证券研究员宣潇君 | | | | | | | 时间 2021 | 年 11 月 30 | 日星期二下午 | | | | | | | | | | ...

编号：2022-001 证券代码：000705 证券简称：浙江震元 浙江震元股份有限公司投资者关系活动记录表 | --- | --- | --- | |--------------------|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系 | √特定对象调研 | □分析师会议 | | 活动类别 | | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □现场参观 □其他（请文字说明其他活动内容） | | 参与单位 名称 | | 中信证券朱奕彰、沈睦钧、徐炯棋，中晶国融章鸿斌 | | | | | | 时间 2022 | 年 1 月 17 | 日星期一下午 | | 地点 公司会议室 | | | | 上市公司 接待人员 | 公司董秘、证代 | | | | ...

证券代码：000705 证券简称：浙江震元 浙江震元股份有限公司投资者关系活动记录表 编号：2022-003 | --- | --- | --- | --- | --- | |-----------------------|-----------------------------------|--------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：000705 证券简称：浙江震元 公告编号：2022-040 公司负责人吴海明先生、主管会计工作负责人柴军先生及会计机构负 责人（会计主管人员）丁佩娟女士声明：保证季度报告中财务报表的真实、 准确、完整。 浙江震元股份有限公司 2022 年第三季度报告 浙江震元股份有限公司 董事长：吴海明 二〇二二年十月二十八日 浙江震元 2022 年第三季度报告 重要提示内容 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承 担个别和连带的法律责任。 适用 □ 不适用 单位：元 审计师发表非标意见的事项 □ 适用 不适用 一、主要财务数据 （一）主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上 | 年初至报告期末 | 年初至报告期末比 | | --- | --- | --- | --- | --- | | | | 年同期增减(%) | | 上年同期增减（%） | | 营业收入（元） | 1,103,778,395.45 | 22.05% | 3,072,140,100.78 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥1,968,361,705.33, representing a 13.80% increase compared to ¥1,729,677,137.91 in the same period last year[20]. - The net profit attributable to shareholders of the listed company decreased by 13.18% to ¥38,217,373.51 from ¥44,020,728.52 year-on-year[20]. - The net cash flow from operating activities improved by 50.25%, reaching -¥61,343,605.85, compared to -¥123,292,324.65 in the previous year[20]. - The basic earnings per share decreased by 15.38% to ¥0.11 from ¥0.13 in the same period last year[20]. - Total assets at the end of the reporting period were ¥2,943,424,045.29, a decrease of 1.44% from ¥2,986,396,531.76 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company increased by 2.25% to ¥1,895,285,360.83 from ¥1,853,653,536.89 at the end of the previous year[20]. - The cost of goods sold increased by 16.60% to ¥1,608,228,014.39 from ¥1,379,305,933.81, resulting in a gross profit margin decrease[51]. - Research and development expenses rose by 37.02% to ¥19,353,662.86, attributed to increased investment in R&D activities[51]. - The company reported a significant increase in investment cash flow, with a net of ¥163,938,911.03, a 376.31% rise due to the maturity of financial products[51]. - Domestic revenue accounted for 99.47% of total revenue, with a year-on-year growth of 13.38%, while international revenue surged by 267.72% to ¥10,370,530.38[52]. Strategic Initiatives - The company plans not to distribute cash dividends or issue bonus shares[7]. - The pharmaceutical industry is expected to benefit from national policies supporting health industry development, particularly following the "Healthy China" strategy[28]. - The company aims to significantly improve its health service capabilities by 2025, in line with national strategies for traditional Chinese medicine development[30]. - By 2025, the company plans to cultivate 1-3 large digitalized pharmaceutical distribution enterprises with sales exceeding 500 billion yuan, and 5-10 specialized retail chain enterprises with sales over 50 billion yuan[33]. - The company has launched 14 new health products, including powdered Ganoderma lucidum spores and Huangjing sesame pills, as part of its health product development initiative[37]. - The company has initiated the "Health Hundred Products" plan, focusing on the development of new health products and expanding its market presence[40]. - The company has signed strategic cooperation agreements with several institutions, including Zhejiang University and Heilongjiang Zhenbaodao Pharmaceutical, to promote industry upgrades[40]. Market Conditions - The retail pharmacy sector is entering a phase of stock competition, with an expected increase in the scale of the pharmaceutical distribution market due to aging population and rising health service demands[31]. - The company faced significant operational pressure due to strict COVID-19 control measures and rising raw material costs, impacting production and operations[39]. - The company is closely monitoring national policy trends and adjusting its operational strategies to mitigate risks associated with industry policy changes[69]. - The company faces intensified competition in the pharmaceutical distribution sector, with a risk of increased market pressure due to the "national leader + regional leader" competitive landscape[70]. Operational Developments - The company has established three new subsidiaries: Zhenyuan Biotechnology, Zhenyuan Health Technology, and Zhenyuan Import & Export, enhancing its product and service offerings in the health industry[34]. - The company accelerated project construction, completing land acquisition for a 160-acre modern pharmaceutical industrial cluster and advancing the digital transformation in healthcare logistics[41]. - The company expanded its pharmacy network by opening 4 new direct-operated stores and optimizing 4 existing ones, increasing the total number of medicinal herb bases to 94, covering over 20,000 acres[41]. - The company has been awarded honors such as the top 100 pharmaceutical wholesale enterprises in China, reflecting its strong market performance[34]. - The company has developed a comprehensive industry chain, integrating drug research and development, production, wholesale, retail, and health services, enhancing its competitive strength[47]. Research and Development - The company has increased its R&D investment significantly, resulting in a substantial rise in R&D expenses compared to the previous year[68]. - The company recognizes the high risks associated with drug research and development, which can take over 10 years and may face regulatory challenges[71]. - The company will strengthen collaboration with research institutions and increase R&D investment to accelerate drug innovation and consistency evaluation of generic drugs[71]. Environmental and Social Responsibility - The company is committed to complying with environmental regulations and increasing investment in environmental protection measures[73]. - The company is classified as a key pollutant discharge unit, with a total discharge of 2,336.93 tons of hazardous waste, but reported no exceedance of discharge standards[81]. - Zhenyuan Pharmaceutical has implemented standardized management of hazardous waste, including classification, collection, and disposal, with a dedicated storage area that meets regulatory requirements[83]. - The company has actively participated in pandemic prevention efforts, establishing 14 nucleic acid testing sites and forming a volunteer team of 540 individuals[88]. Shareholder Information - The company reported a total of 334,123,286 shares outstanding, with 15.64% being restricted shares and 84.36% being unrestricted shares[114]. - The largest shareholder, Shaoxing Zhenyuan Health Industry Group Co., Ltd., holds 24.93% of the shares, totaling 83,300,474 shares[121]. - The company has a total of 30,280 common stock shareholders at the end of the reporting period[121]. Financial Reporting and Compliance - The company’s financial statements are prepared based on the assumption of going concern, with no significant doubts regarding its ability to continue operations for the next 12 months[136]. - The company’s financial reports comply with the requirements of the enterprise accounting standards, reflecting its financial position and operating results accurately[137]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[96].

证券代码：000705 证券简称：浙江震元 公告编号：2022-024 浙江震元股份有限公司 关于参加 2022 年浙江辖区上市公司投资者网上集体接待日 暨 2021 年度业绩说明会活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的沟通交流，提升公司投资者关系管理水 平，浙江震元股份有限公司（以下简称"公司"）将参加由中国证券 监督管理委员会浙江监管局指导、浙江上市公司协会与深圳市全景网 络有限公司共同举办的辖区上市公司投资者网上集体接待日主题活 动。具体安排如下： 一、业绩说明会安排 1、召开时间：2022 年 5 月 13 日（星期五）15:00-17:00。 2、参会人员：公司董事长吴海明；副董事长、总经理陈富根先 生（代行财务总监）；董事会秘书周黔莉女士（如有特殊情况，参与 人员会有调整）。 3、参会方式：本次年度业绩说明会将采用网络远程的方式举行， 投资者可登陆全景网"投资者关系互动平台"（http://ir.p5w.net） 参与本次年度业绩说明会。 二、征集问题事项 为提高互动交流的效率，现提前向所有关心公司的投资 ...

证券代码：000705 证券简称：浙江震元 公告编号：2022-022 浙江震元股份有限公司 2022 年第一季度报告 浙江震元股份有限公司 董事长：吴海明 二〇二二年四月二十八日 浙江震元股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明： 保证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 （一）主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 否 单位：元 | | | . 1 | T | . | | | | --- | --- | --- | --- | --- | --- | --- | | | . 1 | 1 | . | | | | | | | . | | . | Л | 9 1 | | | 本报告期 | 上 ...